PPI Test in GP Patients
|ClinicalTrials.gov Identifier: NCT00318084|
Recruitment Status : Completed
First Posted : April 26, 2006
Last Update Posted : August 17, 2007
|Condition or disease||Intervention/treatment||Phase|
|GERD||Drug: Esomeprazole Procedure: Ambulatory 24-hour esophageal pH-monitoring||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||100 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Proton Pump Inhibitor Test in Reflux Disease: a Study Using Nexium in General Practice Patients|
|Study Start Date :||January 2003|
- Diagnostic test characteristics and the positive and negative predictive value of a 2-week Nexium-based PPI test using symptom analysis of 24-hour esophageal pH monitoring as gold standard.
- To assess the optimal duration of a Nexium-based PPI test, and the predictive value of different symptoms for presence of reflux-related symptoms.
- Obtain information on patient satisfaction, the course of reflux symptoms, the consumption of acid suppressing drugs, the disease-related quality of life at a follow up periods of 3 months in patients with a positive and negative PPI test.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00318084
|Study Director:||AstraZeneca Netherlands Medical Director||AstraZeneca|